The health ministry has decided to let men under 30 who received Moderna Inc.’s COVID-19 vaccine for their first shot switch to Pfizer Inc.’s vaccine for their second.
The decision, made Friday during a meeting of experts, took into account the higher incidence of heart muscle inflammation in young people who received the Moderna shot than those who were given the Pfizer inoculation.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.